Analysis: Merck's statins turn up more muscle side effects than their rivals

Statins have long come with safety worries, but a new analysis shows that Merck & Co.'s ($MRK) products may carry more than their brethren. Pacing side effects data, Advera Health Analytics found that muscle-related side effects--which are commonly linked to the drugs--show up more often in the New Jersey giant's Zocor, Mevacor and Vytorin than in drugs in the rest of the class. More from FiercePharma

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.